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Purpose: Protamine reversal of heparin anticoagulation during cardiovascular surgery may 
cause severe hypotension and pulmonary hypertension. A novel protamine variant, 
[ + 18RGD ], has been developed that effectively reverses heparin anticoagulation without 
toxicity in canine experiments. Heretofore, human studies have not been undertaken. 
This investigation hypothesized that [+ 18RGD] would effectively reverse heparin anti- 
coagulation of human blood in vitro. 
Methods: Fifty patients who underwent anticoagulation therapy during vascular surgery 
had blood sampled at baseline and 30 minutes after receiving heparin (150 IU/kg).  
Activated otting times were used to define specific quantities of [ + 18RGD] or prota- 
mine necessary to completely reverse heparin anticoagulation i  the blood sample of each 
patient. These defined amounts of [+18RGD] or protamine were then administered to 
the heparinized blood samples, and percent reversals of activated partial thromboplastin 
time, thrombin clotting time, and antifactor Xa/ I Ia  levels were determined. In addition, 
platelet aggregation assays, as well as platelet and white blood cell counts were per- 
formed. 
Results: [+ 18RGD] and protamine were equivalent in reversing heparin as assessed by 
thrombin dotting time, antifactor Xa, antifactor I Ia levels, and white blood cell changes. 
[ + 18RGD], when compared with protamine, was superior in this regard, as assessed by 
activated partial thromboplastin time (94.5 + 1.0 vs 86.5 + 1.3%zi, respectively; p < 
0.001) and platelet declines (-3.9 - 2.9 vs -12.8 + 3.4 per mm 3, respectively; p = 
0.048). Platelet aggregation was also decreased for [ +18RGD] compared with prota- 
mine (23.6 + 1.5 vs 28.5 + 1.9%, respectively; p = 0.048). 
Conclusions: [+18RGD] was as effective as protamine for in vitro reversal of heparin 
anticoagulation by most coagulation assays, was statistically more effective at reversal 
than protamine by aPTT assay, and was associated with lesser platelet reductions than 
protamine. [+18RGD], if less toxic than protamine in human beings, would allow for 
effective clinical reversal of heparin anticoagulation. (J Vasc Surg 1997;26:1043-8.) 
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depressed cardiac function, and even death. ~ Prota- 
mine may also cause an allergic anaphylactic-type 
reaction in certain patients. 
A novel protamine variant, [+ 18RGD], has been 
developed in a canine model, that when compared 
with equivalent and clinically applicable doses ofpro- 
tamine has significantly ess toxicity for the reversal of 
standard unfractionated heparin and low-molecular 
weight heparin. 2,3 In addition, [+ 18RGD] has also 
been found to effectively reverse the antifactor Xa 
activity of low-molecular weight heparins in canine 
experiments. 2,3The purpose of this investigation was 
to determine whether [+18RGD] would reverse 
heparin anticoagulation aseffectively as protamine in 
vitro using human whole blood. 
MATERIALS AND METHODS 
Peptide synthesis. The protamine variant pep- 
tide constructed for this study was [+18RGD], 
Acetyl- EA(R2A2R2A)4RzGRGDSPA-Amide. This 
structure compares with n-protamine (the main com- 
ponent of protamine) PR4SaRPVtLsPRVSR6G2R4 
(A, Alanine; D, aspartic acid; E, glutamic acid; G, 
glycine; P, proline; R, arginine; S, serine; and V, 
valine). [+18RGD] was synthesized such that the 
number of arginine (R) residues determined a total 
peptide cationic charge of + 19, with the standard 
protamine charge being +21. [+18RGD] was syn- 
thesized on preloaded Tentagel (Rapp Polymer, Inc., 
Tubingen, Germany) with 9-fluorenylmethoxycar- 
bonyl-amino acid derivatives on a peptide synthe- 
sizer (Applied Biosynthesis 433; Applied Biosystems, 
Foster City, Calif.) using conditional deprotection 
plus single coupling? Hydroxybenzotriazolyl esters 
of the 9-fluorenylrnethoxycarbonyl-amino acids 
were formed using 2-(1H benzotriazol-l-yl)- 1,1,3,3- 
tetramethyluronium hexafluorophosphate (HBTU) 
as an activation agent. Coupling and deprotection of
the nascent peptide chain was performed using stan- 
dard conditions for the synthesizer (FastMOC cy- 
cles). Cleavage and final &protection occurred in 
90% trifluoroacetic acid containing 5% ethanedithol, 
2.5% thioanisole, and 2.5% anisole, for 2 hours at 
room temperature. The [ + 18RGD] was then precip- 
itated from the trifluoroacetic acid by addition of 20 
volumes of diethyl ether at -20 ° C. Purification was 
by reversed-phase high-performance liquid chroma- 
tography (HPLC) on a 5 X 25 cm preparative re- 
versed-phase column at a flow rate of 17 ml/min 
for 90 minutes, with a gradient from 5% to 60% 
acetonitrile containing 0.1% trifluoroacetic acid. It 
was subsequently desalted on gel filtration columns 
(Sephadex G- 15; Pharmacia, Piscataway, N.J. ) equil- 
ibrated with 1N acetic acid and then freeze dried. 
The [+18RGD] produced in this manner was char- 
acterized by amino acid analysis, analytical reversed- 
phase HPLC, and mass spectroscopy to confirm 
purity and structure before use. Commercially avail- 
able clinical protamine (protamine sulfate; Eli Lilly & 
Co., Indianapolis; 10 mg/ml) derived from salmon 
sperm was used for comparison studies. 
Human patients. Fifty patients, 29 men and 21 
women, with a mean age of 67 years, were included 
in this investigation. The study was performed in 
accordance with the University of Michigan Medical 
School Institutional Review Board for Human Sub- 
ject Research (IRBMED 1996-327). These patients 
underwent a variety of peripheral vascular proce- 
dures, including 20 cerebrovascular reconstructions, 
12 abdominal aortic aneurysm resections, 10 lower 
extremity revascularization procedures, ix renal ar- 
tery procedures, and two venous reconstructions. 
These patients exhibited typical risk factors, includ- 
ing hypertension i 80% of patients, smoldng or a 
history of smoking in 66%, hyperlipidemia n 36%, 
and diabetes mellitus in 18%. Sixty-two percent of 
the patients were taldng aspirin or other antiplatelet 
compounds at the time of the study. The surgical 
procedures were performed by five different staff sur- 
geons at the University of Michigan Medical Center. 
The anesthetic management and sampling of blood 
were undertaken by two staff anesthesiologists a  the 
Medical Center. Coagulation and hematologic stud- 
ies were performed by the authors in the Jobst Re- 
search Laboratories of the University of Michigan. 
Peripheral venous bloodsamples were obtained 
at the beginning of the operation to establish base- 
line coagulation and hematologic parameters. Pa- 
tients (n = 50) were anticoagulated with standard 
unfractionated pork heparin (Elkins-Sinn, Inc., 
Cherry Hill, N.J.), 150 IU/kg. A second set of 
blood samples was obtained for in vitro coagulation 
and hematologic tests 30 minutes after heparin ad- 
ministration from the arterial line. At least 10 ml 
of blood was first aspirated before obtaining the 
blood sample to be tested so that the flush solution in 
the arterial ine would not influence results. An acti- 
vated clotting time (ACT) was used to calculate 
[ + 18RGD] and protamine concentrations required 
to reverse heparin anticoagulation in vitro. 
The drug concentration of [ + 18RGD] and pro- 
tamine was determined by modifying the standard 
protamine dose assay (International Technidyne 
Corp., Edison, N.J.) used with the Hemachron ACT 
system for each individual patient. This modified 
test, known as the protamine dose assay, provided a 
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Table I. Percent reversal of coagulation values and hematologic assays 
[+ 18R GD] Protamine p 
Drug concentration studied (Ixg/ml) 18.8 -+ 0.7 (n = 50) 17.8 +- 0.3 (n = 50) NS 
aPTT (% reversal) 94.5 _+ 1.0 (n = 50) 86.5 + 1.3 (n = 50) <0.001 
TCT (% reversal) 98.5 -+ 0.7 (n = 50) 99.6 + 0.1 (n = 50) NS 
Antifactor Xa (% reversal) 89.7 -+ 1.4 (n = 48) 90.2 + 1.2 (n = 47) NS 
Antifactor IIa (% reversal) 96.8 + 1.0 (n = 48) 96.6 + 0.8 (n = 47) NS 
Platelet count (%A) -3 .9  _+ 2.9 (n = 50) -12 .8  + 3.4 (n = 50) 0.048 
Platelet aggregation (%) 23.6 + 1.5 (n = 44) 28.5 + 1.9 (n = 42) 0.048 
White blood cell count (%A) 2.7 _+ 3.6 (n = 50) -2 .6  + 3.3 (n = 50) NS 
simple method for [+ 18RGD] and protamine titra- 
tion. The protamine dose assay adopts the principles 
of in vitro dose-response h parin neutralization, in
which varying amounts of protamine are added to 
samples of the patient's heparinized blood and the 
ACT is determined for each sample. ACT data, plot- 
ted against the in vitro protamine concentration, 
allows the construction of a dose response curve that 
depicts heparin neutralization. In the current investi- 
gation, the protamine dose assay was modified by 
using diluted concentrations of both [+ISRGD] 
and protamine to develop a dose-response curve for 
each compound. Briefly, standard oses of 30 txl and 
10 txl of [ + 18RGD] and protamine solutions with 
drug concentrations of 1 mg/ml were added to dif- 
ferent Hemachron tubes (Celite containing) with 2 
ml of the patient's blood added per tube to deter- 
mine ACT reversal for each concentration. This pro- 
vided [ + 18RGD] or protamine concentrations of 15 
btg/ml and 5 Ixg/ml in the tubes. Based on the 
baseline ACT and ACT reversal values obtained for 
each standard dose of [+18RGD] or protamine, 
specific drug concentrations were extrapolated from 
the heparin neutralization curve that produced com- 
plete heparin anticoagulation reversal. These specifi- 
cally defined rug concentrations of [ + 18RGD ] and 
protamine were then added to additional blood sam- 
ples for completion of the coagulation and hemato- 
logic studies, including the activated partial throm- 
boplastin time (aPTT), thrombin clotting time 
(TCT), antifactor Xa and antifactor IIa activity, 
platelet count and aggregation, and white blood cell 
count. 
Coagulation and hematologic studies. The 
aPTT assays were performed on 0.1 ml platelet-rich 
plasma with 0.1 ml rabbit cephaloplastin (Baxter, 
Miami, Fla.) and 0.1 ml of 0.02 mol/L CaCI 2 added 
as an activator on a fibrometer (Baxter). TCT sam- 
ples were measured on a fibrometer using 0.2 ml 
platelet-rich plasma nd 0.1 ml TCT reagent (Amer- 
ican Dade, Miami, Fla.). The aPTT and TCT mea- 
surements were performed in duplicate, and the re- 
suits were averaged. 
Antifactor Xa and antifactor IIa measurements 
were performed after cold centrifugation (3000 rpm 
for 20 minutes at 4 ° C) of citrated blood previously 
stored on ice after collection. In the antifactor Xa 
assay (Coatest Heparin, KB Vitrum, Stockholm, 
Sweden), excess antithrombin followed by factor Xa 
was added to the plasma sample, which was then 
reacted with a chromogenic substrate S-2222. 4The 
antifactor IIa assay was performed by adding throm- 
bin (factor IIa) followed by the chromogenic sub- 
strate S-2238, to plasma samples previously incu- 
bated with excess antithrombin III. Antifactor Xa 
and antifactor IIa activity was inversely proportional 
to absorbance at405 nm, which indicated the quan- 
tity of remaining uninhibited factor Xa or IIa, as a 
measure of residual heparin activity. Heparin concen- 
trations were then determined from standard curves 
constructed from known amounts of heparin and 
their corresponding absorbances for both assays. 
Platelet aggregation studies were performed us- 
ing platelet-rich plasma derived by centrifugation 
(25 ° C) ofheparinized blood at 800 to 1000 rpm for 
10 minutes, and platelet poor plasma prepared by 
centrifugation of the supernatant a 3000 rpm for an 
additional 15 minutes. Platelet-rich plasma, 450 txl, 
was stimulated by adding 2 x 105 mol/L adenosine 
5'-diphosphate (BioData Corp., Horsham, Pa.), and 
aggregation was observed for 3 minutes in a platelet 
aggregometer (Sienco, Inc., Turkey Creek, Colo.), 
with the platelet-rich plasma set at 0 transmission and 
platelet-poor plasma set at 100% transmission. All 
platelet aggregation measurements were made in du- 
plicate, and the maximum percent aggregation was 
recorded. White blood cell and platelet counts were 
determined with a manual hemocytometer using a 
dilution red cell lysis method (Unnopette, Becton- 
Dickinson, Rutherford, N.J.). 
In determining [ + 18RGD] and protamine con- 
centrations, aPTT, TCT, platelet counts, and white 
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Table II. Coagulation values and hematologic assays 
Platelet White 
aPTT TCT Anti-fXa Anti-fIIa Platelet aggregation blood cell 
(see) (see) [HeplU/ml] [HepIU/ml] count/ram 3 (%) count/ram a 
Baseline 28.6 + 0.5 13.3 _+ 0.3 0.64 _+ 0.02 [0.14] 1.41 -+ 0.02 [0.04] 190,220 _+ 8528 27.2 _+ 1.8 6534 _+ 316 
s /p  Heparin >100 >100 0.09 + 0.01 [0.82] 0.35 _+ 0.02 [0.62] 180,220 -+ 7853 31.6 _+ 1.8 6291 +_ 297 
s /p  Protamine 38.1 + 1.0 13.0 _+ 0.2 0.59 + 0.02 [0.21] 1.41 _+ 0.02 [0.04] 152,000 _+ 6666 28.5 -+ 1.9 6635 -+ 309 
s /p  [+18RGD] 31.6 _+ 0.9 14.2 +_ 0.6 0.58 + 0.02 [0.21] 1.42 + 0.02 [0.04] 169,820 + 7892 23.6 _+ 1.5 6974 ± 311 
[+18RGD] vs. p < 0.001 NS NS NS NS p = 0.048 NS 
protaminc 
Anti-fXa, Antifactor Xa absorbance at405 nm; Anti-JIIa, antifactor IIa absorbance at405 nm; [HeplU/ml], heparin concentration. 
blood cell counts, 50 observations were made for 
each drug. The numbers of observations were occa- 
sionally less than 50 per drug as a result of technical 
reasons in determining antifactor Xa activity, antifac- 
tor IIa activity, and platelet aggregation. 
Statistical analysis of the parametric data included 
an unpaired two-tailed Student t test. The Mann- 
Whimey statistical test was used for analysis of the 
nonparametric data. Statistical significance was estab- 
lished at a p level of 0.05 or less. Data are expressed as 
mean + SE of the mean. Results are presented as 
both percent reversal (Table I) and as the absolute 
values (Table II) for coagulation assay and the hema- 
tologic test data. 
RESULTS 
Drug concentrations required for complete re- 
versal of heparin anticoagulation, asdetermined by 
the ACT dose-response curves, were not statistically 
different between [+18RGD] and protamine 
(18.8 + 0.7 Ixg/ml and 17.8 + 0.3 txg/ml, respec- 
tively). Using these specific drug concentrations for 
reversing the anticoagulant effects in the patient's 
heparinized blood samples, there was no significant 
difference between [+18RGD] and protamine as 
measured by the TCT, antifactor Xa activity, and 
antifactor IIa activity (Table I). However, there was a 
statistically significant difference (p < 0.001 ) in 
heparin anticoagulation reversal as mcasurcd by the 
aPTT after [+18RGD] administration (94.5% -+ 
1.0%) compared with protamine administration 
(86.5% + 1.3%). Absolute aPTT values were 28.6 + 
0.5 seconds at baseline, greater than 100 seconds 
after heparin, 38.1 --- 1.0 seconds after protamine, 
and 31.6 --_ 0.9 seconds after [+ 18RGD]. The abso- 
lute values for each drug (Table II) were also statisti- 
cally different (p < 0.001). 
There was a statistically greater (p = 0.048) 
thrombocytopenia in the protamine group compared 
with the [+18RGD] group. The mean decline in 
platelet count for [+18RGD] was -3.9% + 2.9%, 
whereas for protamine it was -12.8% + 3.4%. Abso- 
lute platelet counts per mm 3 were 190,220 _+ 8528 
at baseline, 180,220 + 7853 after heparin, 
152,000 _+ 6666 after protamine, and 169,820 _+ 
7892 after [+18RGD] (Table II). There was also a 
significant decrease (p = 0.048) in platelet aggrega- 
tion after [ + 18RGD ] administration compared with 
that after protamine administration (Table II). Plate- 
let aggregations were 27.2% _+ 1.8% at baseline, 
31.6% -+ 1.8% after heparin, 28.5% _+ 1.9% after 
protamine, and 23.6% _+ 1.5% after [+I8RGD].  
There was essentially no difference between aggrega- 
tions after protamine or [ + 18RGD] in those patients 
who were taking aspirin or other antiplatelet com- 
pounds (31%, 25%) or those who were not taking 
aspirin or other antiplatelet compounds (25%, 21%). 
As expected, baseline platelet aggregations were 
greater in those patients who were not taldng aspirin 
or related compounds (30.2% + 3.5%) than those 
who were taking aspirin or related compounds 
(25.5% -+ 2.1%), although the difference was not 
statistically different. There was a slight and non- 
statistically significant increase in the white blood cell 
count after [+18RGD] administration compared 
with the slight decline in the white blood cell count 
after protamine administration (Table II). White 
blood cell counts per mm 3 were 6534 -2_ 316 at 
baseline, 6291 _+ 297 after heparin, 6635 + 309 
after protamine, and 6974 -+ 311 after [ + 18RGD ]. 
DISCUSSION 
Unfractionated hepariu is a mixture of sulfated 
polysaccharides, some of which bind to antithrombin 
III. This mixturc produces a conformational change 
that converts antithrombin III from a slow inhibitor 
to a rapid inhibitor of thrombin (factor IIa), factor 
Xa, and other serine proteases in coagulation. 5-7 Ac- 
tivated factors II and X are the most sensitive factors 
to the heparin-antithrombin III complex. Prota- 
mine, a highly positively charged compound, re- 
verses the anticoagulant effect of heparin, a highly 
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negatively charged compound. Electrophoretic stud- 
ies of the heparin-antithrombin III complex in the 
presence or absence ofprotamine suggests that when 
protamine neutralizes heparin by binding to it, anti- 
thrombin III is reverted to its previous unpotentiated 
state, thus decreasing anticoagulation. 8 
Protamine sulfate is the only current Food and 
Drug Administration-approved agent for the rever- 
sal ofheparin anticoagulation. However, it is known 
to be associated with potentially life-threatening 
complications when administered to reverse heparin, 
including systemic hypotension, pulmonary artery 
hypertension, depressed cardiac output, and marked 
declines in oxygen use. Deaths may follow extreme 
reactions) In two small series, systemic hypotension 
was found in 3% to 5% of patients who underwent 
peripheral vascular surgical procedures, 9 and pulmo- 
nary hypertension has been seen in up to 5% of 
patients who undergo cardiopulmonary b pass pro- 
cedures) ° In this regard, adverse responses to prota- 
mine, including hypotension, pulmonary artery hy- 
pertension, anaphylaxis, and death, were noted in 
5.3% and 4.0% of cases reported by 284 members of 
the Society for Vascular Surgery and 362 members of 
the European Society for Vascular Surgery, respec- 
tively, n In addition, stroke accompanying carotid 
endarterectomy has been linked to the use of prota- 
mine to reverse heparin anticoagulation. 12,13 Al- 
though a number of mechanisms may be responsible 
for protamine toxicity, it appears that protamine it- 
self, not heparin or the protamine-heparin complex, 
is responsible for toxicity, z4 Protamine is known to 
be directly toxic to endothelial cells and cardiac myo- 
cytes.l~,16 
Protamine is purified from salmon sperm and is a 
heterogeneous mixture of cationic polypeptides. The 
major component of protamine is a 32-amino acid 
peptide with the sequence PR4SaRPVR6PRVSR6G2R4 
(wherein P is prolene; R, arginine; S, serine; V, va- 
line; G, glycine). 17 The amino acid arginine accounts 
for two thirds of the total sequence and is responsible 
for the total positive charge ofprotamine. Both hep- 
arin anticoagulation reversal efficacy and toxicity 
appear dependent on protamine's positive charge, 
as documented by previous tudies from our labora- 
tory) 8 In these previous canine studies, the optimal 
charge for reversal of standard unfractionated hepa- 
rin was found to be between + 16 and + 18.18 It was 
subsequently recognized that modifying the charge 
and structure of the molecule improved reversal effi- 
cacy while reducing toxicity. 19,2° The [+18RGD] 
compound followed placement of acetyl and amide 
groups on the end of the + 18 charge compound, 
substitution of a glutamic acid with prolene in the 
backbone of this molecule, and the addition of an RGD 
side group with arginine amino acids making up posi- 
tive charges of the molecule. 2,a This compound, with 
the structure [acetyI-EA(RzA2R2A)4R2GRGDSPA- 
amide], was nontoxic in canine experiments during 
reversal of both standard unfractionated heparin and 
low-molecular weight heparin anticoagulation, with 
an etficacy equivalent to standard protamine. In fact, 
[ + 18RGD] was much more effective than protamine 
in reversing the antifactor Xa activity produced by 
two different low-molecular weight heparins. 2,3 
The present investigation confirms that 
[+18RGD] is effective for the reversal of heparin 
anticoagulation fhuman blood in vitro, with equal 
efficacy compared with protamine as measured by 
TCT, antifactor Xa, and antifactor IIa reversal. Im- 
portantly, heparin activity, as measured chromogeni- 
cally using antifactor Xa and antifactor IIa levels 
(Table II), returned close to baseline levels after 
administration of both [ + 18RGD] and protamine. 
[+18RGD] was more effective than protamine at 
reversing heparin anticoagulation as measured by 
aPTT values and was nearly equal in potency as 
measured by ACT values. 
The variant [+ 18RGD ] caused alesser decline in 
platelet level than did protamine. Platelet aggrega- 
tion was decreased slightly, as would be expected as a 
result of the presence of the RGD receptor on 
[+18RGD]. Unbound [+ISRGD], by binding to 
platelet RGD receptors, would prevent platelet 
clumping through an inhibition of fibrinogen, which 
binds platelets to platelets through RGD receptors. 
This prevention ofplatelet clumping by [ + 18RGD] 
and the preservation ofplatelet numbers uggest that 
despite less platelet aggregation to adenosine diphos- 
phate after [+ 18RGD] reversal compared with pro- 
tamine, there should be no detrimental bleeding 
effects. In addition, no elevations in mucosal bleed- 
ing times have been noted in canine studies after 
either standard heparin or low-molecular weight 
heparin neutralization with [+ISRGD]. 2,3 In addi- 
tion, although not statistically different, no decline in 
white blood cell count occurred in the [+ISRGD] 
group, compared with a slight decline in the prota- 
mine group. It has been hypothesized that prota- 
mine-induced changes in leukocyte adhesiveness are 
charge-mediated, and the greater the charge, the 
more likely it is for leukocytes to adhere to each other 
and clump. 21 As standard protamine carries a charge 
of +21 and [+18RGD] carries a charge of +19, 
leukocyte declines might be expected to be greater 
with protamine than [ + 18RGD]. 
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[+18RGD], if found less toxic in clinical use, 
would have a role in effective heparin anticoagulation 
reversal in patients. The results of this in vitro inves- 
tigation, documenting the efficacy of [+18RGD] 
reversal of heparin anticoagulation, are important in 
justifying future clinical studies of this drug's in vivo 
safety and effectiveness. 
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